

# Presentation of proposed board members

The Nomination Committee's proposal AGM 2019 (item 11 in the proposed agenda)



Re-election

## David Laskow-Pooley

Chairman since 2017. Director since 2016.

**Born:** 1954

**Education:** BSc Pharmacy (1st), Pharmaceutical/ Chemical engineering specialty and QP, Sunderland School of Pharmacy.

**Other assignments:** CEO of Pharmafor Ltd, England, and Director of the Board in Marker Therapeutics Inc. (England) and LREsystem Ltd, (England).

**No. of shares in NeuroVive:** 30,552

**Other:** Non-affiliated to the Company, the management and to major owners.



Re-election

## David Beijker

Director since 2017.

**Born:** 1975

**Education:** M.Sc. (Econ.), Stockholm School of Economics.

**Other assignments:** CEO of Affibody Medical AB

**No. of shares in NeuroVive:** 30,552

**Other:** Non-affiliated to the Company, the management and to major owners.



New election

## Magnus Persson

**Born:** 1960

**Education:** MD and PhD in physiology, Karolinska Institute, Stockholm

**Other ongoing assignments:** Persson is Chairman of the board in Attgeno AB, Cantargia AB, SLS Invest AB, Galecto Biotech AB, Perma Ventures AB, Addi Medical AB, and Addi Optioner AB. Director of the board in Immunicum Aktiebolag, Karolinska Development AB, Själbådan AB, Gyros Protein Technologies Holding AB, Cerecor Inc, and Medical Prognosis Institute A/S.

**No. of shares in NeuroVive:** -

**Other:** Associate professor in physiology at the Karolinska Institute in Stockholm. Persson has a large amount of experience in the fields of medicine, life sciences and biotech-financing. Persson has previously led development teams in clinical phase II and phase III programmes in the pharmaceutical industry and has founded and led private as well as public biotech and medtech companies, either as chairman or member of the board, in Europe and the USA. Persson has also been involved in multiple IPOs. Independent in relation to the Company and its management and the Company's major shareholders.



Re-election

## Denise Goode

Director since 2018

**Born:** 1958

**Education:** Chartered Accountant from the Institute of Chartered Accountants in England and Wales. B.Sc. Zoology from The University of Manchester (UK)

**Other ongoing assignments:** Director of the Board of QED Life Sciences Limited, and VP Business Development in AnaMar AB.

**No. of shares in NeuroVive:** -

**Other:** Non-affiliated to the company, the management, and to major owners.



Re-election

## Jan Törnell

Director since 2017.

**Born:** 1960

**Education:** MD and PhD in physiology, University of Gothenburg.

**Other assignments:** CEO and Director of the Board of Innoext AB, Chairman of the Board of LIDDS AB and Glactone Pharma AB, Director of the Board of Diaprost AB, Deputy director of the Board of LIDDS Pharma AB, and partner in P.U.L.S. AB.

**No. of shares in NeuroVive:** 30,552

**Other:** Non-affiliated to the Company, the management and to major owners.